Wednesday, October 30, 2013

NATAP-Treatment of Chronic Hepatitis C: The Revolution!

Treatment of Chronic Hepatitis C: The Revolution!

Jules Levin founder and executive director of National AIDS Treatment Advocacy Project (NATAP) reports on the European AIDS Conference which took place in Belgium from October 16-19.

Mr. Levin offers commentary and slides from Dr. Wedemeyer's presentation; Treatment of Chronic Hepatitis C: The Revolution! which reviews data on new HCV oral IFN-free drug regimens and direct acting activirals in clinical development.

Here are a few sample slides and a bit of commentary, view complete presentation @  NATAP

Treatment of Chronic Hepatitis C: The Revolution!

Heiner Wedemeyer
Hannover Medical School

Commentary From Jules Levin:  
The FDA hearings on Oct 24/25 reviewed Simeprevir+PR for 24 weeks and Sofosbuvir +PR for 12 weeks, and as expected the panels voted unanimously to approve both 19-0 & 15-0. This is just the prelude to next year when the first 2 IFN-free regimens will be considered for approval by the FDA in the early part of 2014 & of course approval is expected, they are Gilead's Sofosbuvir+Ledipasvir & Abbvie's ABT450+ABT267+ABT333 both with and/or without RBV, phase 3 studies are......

"All oral therapy will lead to a change in treatment paradigm"
"The number of treatable patients will dramatically increase! Interferon-Free"
"There is an association between SVR & all-cause mortality & liver-related mortality"


Complete Coverage

No comments:

Post a Comment